Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation
暂无分享,去创建一个
Chad Deisenroth | M. Lindström | Yanping Zhang | Aiwen Jin | Yanping Zhang | C. Deisenroth | Aiwen Jin | Mikael S. Lindström | Gabrielle White Wolf | Gabrielle White Wolf
[1] Petra de Graaf,et al. Critical Role for a Central Part of Mdm2 in the Ubiquitylation of p53 , 2003, Molecular and Cellular Biology.
[2] A. Levine,et al. Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6 , 1998, Molecular and Cellular Biology.
[3] F. Rilke,et al. DISTINCT mdm2/p53 EXPRESSION PATTERNS IN LIPOSARCOMA SUBGROUPS: IMPLICATIONS FOR DIFFERENT PATHOGENETIC MECHANISMS , 1997, The Journal of pathology.
[4] Muyang Li,et al. Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2 , 2003, Science.
[5] A. Weissman,et al. RING Finger Proteins Mediators of Ubiquitin Ligase Activity , 2000, Cell.
[6] E. Yeh,et al. Nucleocytoplasmic Shuttling Modulates Activity and Ubiquitination-Dependent Turnover of SUMO-Specific Protease 2 , 2006, Molecular and Cellular Biology.
[7] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[8] T. Hupp,et al. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. , 2006, Molecular cell.
[9] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[10] M. Schwab,et al. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. , 1995, European journal of cancer.
[11] H. Taubert,et al. Alternative and aberrant splicing of MDM2 mRNA in human cancer. , 2002, Cancer cell.
[12] Y. Xiong,et al. A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation , 2001, Science.
[13] W. Sellers,et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.
[14] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[15] K. Shirouzu,et al. MDM2 interacts with MDMX through their RING finger domains , 1999, FEBS letters.
[16] A. Levine,et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes , 1994, Molecular and cellular biology.
[17] M. Kubbutat,et al. Regulation of HDM2 activity by the ribosomal protein L11. , 2003, Cancer cell.
[18] L. Donehower,et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] I. Weissman,et al. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. , 1993, Genes & development.
[20] T. Allio,et al. Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway , 2003, Molecular and Cellular Biology.
[21] Tony Kouzarides,et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.
[22] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[23] R. Honda,et al. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase , 2000, Oncogene.
[24] M. Dai,et al. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. , 2006, Neoplasia.
[25] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[26] M. Dai,et al. Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition , 2004, Molecular and Cellular Biology.
[27] A. Levine,et al. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] C. Cordon-Cardo,et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] A. Levine,et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.
[30] Shengyun Fang,et al. Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.
[31] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Maki,et al. The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.
[33] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[34] G. Warren,et al. Direct binding of ubiquitin conjugates by the mammalian p97 adaptor complexes, p47 and Ufd1–Npl4 , 2002, The EMBO journal.
[35] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[36] Y. Xiong,et al. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[37] K. Bhat,et al. Essential role of ribosomal protein L11 in mediating growth inhibition‐induced p53 activation , 2004, The EMBO journal.
[38] M. Dai,et al. Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5* , 2004, Journal of Biological Chemistry.
[39] G. Wahl,et al. A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.
[40] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[41] David Hawke,et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. , 2003, Molecular cell.
[42] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[43] D. Lane,et al. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. , 2001, Experimental cell research.
[44] M. Pierotti,et al. Analysis of the molecular species generated by mdm2 gene amplification in liposarcomas , 2001, International journal of cancer.
[45] A. Levine,et al. Molecular Abnormalities of mdm 2 and p 53 Genes in Adult Soft Tissue Sarcomas ' , 2022 .
[46] R. Copeland,et al. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. , 2006, Biochemistry.
[47] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.
[48] R. Tjian,et al. Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.
[49] A. Fersht,et al. Solution structure of the C4 zinc finger domain of HDM2 , 2006, Protein science : a publication of the Protein Society.
[50] K. Tsai,et al. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53 , 2000, Nature Cell Biology.
[51] H. Ke,et al. Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability* , 2006, Journal of Biological Chemistry.
[52] K. Itahana,et al. Inhibition of HDM2 and Activation of p53 by Ribosomal Protein L23 , 2004, Molecular and Cellular Biology.
[53] Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. , 1998, The EMBO journal.
[54] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[55] Guillermina Lozano,et al. MDM2, an introduction. , 2003, Molecular cancer research : MCR.
[56] T. Schlott,et al. POINT MUTATIONS AND NUCLEOTIDE INSERTIONS IN THE MDM2 ZINC FINGER STRUCTURE OF HUMAN TUMOURS , 1997, The Journal of pathology.
[57] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[58] Yanping Zhang,et al. Nucleocytoplasmic Shuttling of p53 Is Essential for MDM2-Mediated Cytoplasmic Degradation but Not Ubiquitination , 2003, Molecular and Cellular Biology.
[59] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[60] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[61] Scott D Emr,et al. Ubiquitin interactions of NZF zinc fingers , 2004, The EMBO journal.
[62] B. Wasylyk,et al. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability , 2001, Oncogene.
[63] T. Pieler,et al. Protein-mediated nuclear export of RNA: 5S rRNA containing small RNPs in xenopus oocytes , 1990, Cell.